Carboplatin + Cisplatin + Docetaxel + Etoposide + Pembrolizumab
Phase 1ActiveDevelopment Stage
Bladder Small Cell Neuroendocrine Carcinoma
Bladder Small Cell Neuroendocrine Carcinoma, Castration-Resistant Prostate Carcinoma, Metastatic Bladder Urothelial Carcinoma, Metastatic Urethral Urothelial Carcinoma, Prostate Carcinoma Metastatic in the Bone, Prostate Neuroendocrine Neoplasm, Prostate Small Cell Carcinoma, Stage III Bladder Cancer American Joint Committee on Cancer ( AJCC) v8, Stage III Prostate Cancer AJCC v8, Stage III Urethral Cancer AJCC v8, Stage IV Bladder Cancer AJCC v8, Stage IV Prostate Cancer AJCC v8, Stage IV Urethral Cancer AJCC v8, Stage IVA Bladder Cancer AJCC v8, Stage IVB Bladder Cancer AJCC v8, Ureter Small Cell Carcinoma, Urothelial Carcinoma
Jan 11, 2019 → Dec 1, 2026
About Carboplatin + Cisplatin + Docetaxel + Etoposide + Pembrolizumab
Carboplatin + Cisplatin + Docetaxel + Etoposide + Pembrolizumab is a phase 1 stage product being developed by Merck for Bladder Small Cell Neuroendocrine Carcinoma. The current trial status is active. This product is registered under clinical trial identifier NCT03582475. Target conditions include Bladder Small Cell Neuroendocrine Carcinoma, Castration-Resistant Prostate Carcinoma, Metastatic Bladder Urothelial Carcinoma.
What happened to similar drugs?
20 of 20 similar drugs in Bladder Small Cell Neuroendocrine Carcinoma were approved
Hype Score Breakdown
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03582475 | Phase 1 | Active |
Competing Products
20 competing products in Bladder Small Cell Neuroendocrine Carcinoma